Watch this webinar from Concept Life Sciences, hosted by Dr. Thomas Pesnot (Concept Life Sciences) and featuring Dr. Debanu Das from Accelero Biostructure, Inc as keynote speaker.
In this webinar, the speakers will cover :
- protein crystallography and its importance in drug discovery.
- challenges in crystallography, structural biology and gene-to-structure for drug discovery and protein engineering.
- significance of our high-throughput crystallography for drug discovery.
- hit generation in drug discovery with our crystallography-based library screening.
- interfacing crystallography with biophysics, medicinal and computational chemistry, biology and our AI in drug discovery.
Presenters
Drug Discovery Services Director
Concept Life Sciences
Thomas (Tom) Pesnot, PhD is Drug Discovery Services Director at Concept Life Sciences since 2024. He has gained over 15 years' experience of leading drug discovery programmes in the academic, biotech, and CRO sectors, and contributed to the development of multiple clinical candidates and marketed drugs.
CEO and Co Founder
Accelero Biostructures
Debanu has over 20 years of experience in high-throughput protein X-ray crystallography, structure-and fragment-based drug discovery and structural biology. His expertise includes structure-function analysis of a broad range of proteins and drug targets (kinases, proteases, antibody-antigen complexes, nuclear receptors, ubiquitin ligases, methylases, polymerases, microbiome enzymes, membrane proteins, transcription factors).
Webinar Host
Concept Life Sciences
Concept Life Sciences is a UK-based drug discovery CRO, helping global pharma and biotech companies accelerate their drug candidate to clinic by offering integrated drug discovery programs.
Additional Content From Concept Life Sciences
Translational Success in Inflammasome Drug Discovery: How Advanced Models and Integrated Assays Can Reduce Attrition
Join Professor Luke O’Neill (Trinity College Dublin) and Dr Elise Malavasi ( Associate Director of Neurosciences Concept Life Sciences) for this webinar that explores recent advances in inflammasome science, and highlights how selecting appropriate in vitro models and meaningful readouts is essential for accurately assessing therapeutic potential.
Uniting biology and digital drug discovery to identify new therapeutic opportunities in neurodegeneration
As the FDA and NIH encourage a shift away from animal testing, there’s growing momentum behind New Approach Methodologies (NAMs) — from advanced in vitro models to computational platforms. In this webinar, Concept Life Sciences and Delta4 present a powerful example of what this future looks like in practice.
The ADMET Toolkit: Impact on Compound Design and Optimisation
Watch this webinar by Concept Life Sciences, hosted by Dr. Thomas Pesnot (Concept Life Sciences) and featuring Dr. Rob Riley as keynote speaker, on the ADMET Toolkit for clinical pharmacokinetics.
Related Content
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.